Liver transplantation in the Nordic countries - An intention to treat and post-transplant analysis from The Nordic Liver Transplant Registry 1982-2013

Bjarte Fosby, Espen Melum, Kristian Bjøro, William Bennet, Allan Rasmussen, Ina Marie Andersen, Maria Castedal, Michael Olausson, Christina Wibeck, Mette Gotlieb, Henrik Gjertsen, Leena Toivonen, Stein Foss, Heikki Makisalo, Arno Nordin, Truls Sanengen, Annika Bergquist, Marie E Larsson, Gunnar Soderdahl, Greg Nowak, Kirsten Muri Boberg, Helena Isoniemi, Susanne Keiding, Aksel Foss, Pål-Dag Line, Styrbjörn Friman, Erik Schrumpf, Bo-Göran Ericzon, Krister Höckerstedt, Tom H Karlsen, Bjarte Fosby, Espen Melum, Kristian Bjøro, William Bennet, Allan Rasmussen, Ina Marie Andersen, Maria Castedal, Michael Olausson, Christina Wibeck, Mette Gotlieb, Henrik Gjertsen, Leena Toivonen, Stein Foss, Heikki Makisalo, Arno Nordin, Truls Sanengen, Annika Bergquist, Marie E Larsson, Gunnar Soderdahl, Greg Nowak, Kirsten Muri Boberg, Helena Isoniemi, Susanne Keiding, Aksel Foss, Pål-Dag Line, Styrbjörn Friman, Erik Schrumpf, Bo-Göran Ericzon, Krister Höckerstedt, Tom H Karlsen

Abstract

Aim and background: The Nordic Liver Transplant Registry (NLTR) accounts for all liver transplants performed in the Nordic countries since the start of the transplant program in 1982. Due to short waiting times, donor liver allocation has been made without considerations of the model of end-stage liver disease (MELD) score. We aimed to summarize key outcome measures and developments for the activity up to December 2013.

Materials and methods: The registry is integrated with the operational waiting-list and liver allocation system of Scandiatransplant (www.scandiatransplant.org) and accounted at the end of 2013 for 6019 patients out of whom 5198 were transplanted. Data for recipient and donor characteristics and relevant end-points retransplantation and death are manually curated on an annual basis to allow for statistical analysis and the annual report.

Results: Primary sclerosing cholangitis, acute hepatic failure, alcoholic liver disease, primary biliary cirrhosis and hepatocellular carcinoma are the five most frequent diagnoses (accounting for 15.3%, 10.8%, 10.6%, 9.3% and 9.0% of all transplants, respectively). Median waiting time for non-urgent liver transplantation during the last 10-year period was 39 days. Outcome has improved over time, and for patients transplanted during 2004-2013, overall one-, five- and 10-year survival rates were 91%, 80% and 71%, respectively. In an intention-to-treat analysis, corresponding numbers during the same time period were 87%, 75% and 66%, respectively.

Conclusion: The liver transplant program in the Nordic countries provides comparable outcomes to programs with a MELD-based donor liver allocation system. Unique features comprise the diagnostic spectrum, waiting times and the availability of an integrated waiting list and transplant registry (NLTR).

Keywords: end-stage liver disease; indication; liver transplantation; organ allocation; outcome; registry.

Figures

Figure 1.
Figure 1.
(A) The total number of first liver transplantations (LTX) performed in the Nordic countries (Denmark, Sweden, Finland and Norway) since 1982 along with the annual number of retransplantations in the same period. (B) The distribution of LTX per. 1 million of the country population (PMP) of the different Nordic countries from 1982 to 2013. (C) Age distribution of recipients at first LTX through the period from 1982 to 2013 for all the Nordic countries combined. (D) The total number of liver recipients older than 60 years (blue), and the same group as the fraction of the total LTX ctivity in the period from 1987 to 2013.
Figure 2.
Figure 2.
(A) Patient Kaplan–Meier survival after first liver transplantation (LTX) between 2001 and 2013, subdivided according to model of end-stage liver disease (MELD) score. (B) Patient Kaplan–Meier survival curves per disease category for first LTX during the period of 1982 and 2013. (C) Patient Kaplan–Meier survival curves stratified by retransplantation status for LTX performed between 1982 and 2013. (D) Patient Kaplan–Meier survival curves according to different time periods between 1982 and 2013.

References

    1. National Institutes of Health Consensus Development Conference: liver transplantation. R I Med J. 1984;67:73–6.
    1. Klein KB, Stafinski TD, Menon D. Predicting survival after liver transplantation based on pre-transplant MELD score: a systematic review of the literature. PLoS ONE. 2013;8:e80661.
    1. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013;58:593–608.
    1. Adam R, Karam V, Delvart V, O’Grady J, Mirza D, Klempnauer J, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR) J Hepatol. 2012;57:675–88.
    1. Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol. 1998;33:99–103.
    1. Escorsell A, Pares A, Rodes J, Solis-Herruzo JA, Miras M, de la Morena E. Epidemiology of primary sclerosing cholangitis in Spain. Spanish Association for the Study of the Liver. J Hepatol. 1994;21:787–91.
    1. Bellentani S, Tiribelli C, Saccoccio G, Sodde M, Fratti N, De MC, et al. Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos Study. Hepatology. 1994;20:1442–9.
    1. van der Poel CL, Ebeling F. Hepatitis C virus: epidemiology, transmission and prevention. Curr Stud Hematol Blood Transfus. 1998;62:208–36.
    1. Christenson B, Bottiger M, Grillner L. The prevalence of hepatitis B in Sweden; a statistical serosurvey of 3381 Swedish inhabitants. Epidemiol Infect. 1997;119:221–5.
    1. Bismuth H, Castaing D, Ericzon BG, Otte JB, Rolles K, Ringe B, et al. Hepatic transplantation in Europe. First Report of the European Liver Transplant Registry. Lancet. 1987;2:674–6.
    1. Roberts MS, Angus DC, Bryce CL, Valenta Z, Weissfeld L. Survival after liver transplantation in the United States: a disease-specific analysis of the UNOS database. Liver Transpl. 2004;10:886–97.
    1. Levy MF, Somasundar PS, Jennings LW, Jung GJ, Molmenti EP, Fasola CG, et al. The elderly liver transplant recipient: a call for caution. Ann Surg. 2001;233:107–13.
    1. Pagano D, Grosso G, Vizzini G, Spada M, Cintorino D, Malaguarnera M, et al. Recipient-donor age matching in liver transplantation: a single-center experience. Transplant Proc. 2013;45:2700–6.
    1. Cholongitas E, Marelli L, Shusang V, Senzolo M, Rolles K, Patch D, et al. A systematic review of the performance of the model for end-stage liver disease (MELD) in the setting of liver transplantation. Liver Transpl. 2006;12:1049–61.
    1. McElroy LM, Daud A, Davis AE, Lapin B, Baker T, Abecassis MM, et al. A meta-analysis of complications following deceased donor liver transplant. Am J Surg. 2014;208:605–18.
    1. Boberg KM. Prevalence and epidemiology of autoimmune hepatitis. Clin Liver Dis. 2002;6:635–47.
    1. Bjoro K, Brandsaeter B, Foss A, Schrumpf E. Liver transplantation in primary sclerosing cholangitis. Semin Liver Dis. 2006;26:69–79.
    1. Bjoro K, Friman S, Hockerstedt K, Kirkegaard P, Keiding S, Schrumpf E, et al. Liver transplantation in the Nordic countries, 1982-1998: changes of indications and improving results. Scand J Gastroenterol. 1999;34:714–22.
    1. Melum E, Schrumpf E, Bjoro K. Liver TX for hepatitis C cirrhosis in a low prevalence population: risk factors and status at evaluation. Scand J Gastroenterol. 2006;41:592–6.
    1. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124:91–6.
    1. Cholongitas E, Burroughs AK. The evolution in the prioritization for liver transplantation. Ann Gastroenterol. 2012;25:6–13.
    1. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464–70.
    1. Kamath PS, Kim WR. The model for end-stage liver disease (MELD) Hepatology. 2007;45:797–808.
    1. Grunnet N, Bodvarsson M, Jakobsen A, Kyllonen L, Olausson M, Pfeffer P, et al. Scandiatransplant report. Transplant Proc. 2009;2010;42:4429–31.
    1. Aune S, Schistad G, Skulberg A. Human liver transplantation without azathioprine. Surg Gynecol Obstet. 1972;135:727–8.
    1. Aune S. Orthotopic liver transplantation. Ann Chir Gynaecol Fenn. 1973;62:175–7.
    1. Abouna GM. Organ shortage crisis: problems and possible solutions. Transplant Proc. 2008;40:34–8.
    1. Martin AP, Bartels M, Hauss J, Fangmann J. Overview of the MELD score and the UNOS adult liver allocation system. Transplant Proc. 2007;39:3169–74.
    1. Stepanova M, Wai H, Saab S, Mishra A, Venkatesan C, Younossi Z. The outcomes of adult liver transplants in the united states from 1987 to 2013. Liver Int. 2015 [Epub ahead of print]
    1. Jain A, Reyes J, Kashyap R, Dodson SF, Demetris AJ, Ruppert K, et al. Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg. 2000;232:490–500.
    1. Aberg F, Gissler M, Karlsen TH, Ericzon BG, Foss A, Rasmussen A, et al. Differences in long-term mortality among liver transplant recipients and the general population: A population-based Nordic study. Hepatology. 2015;61:668–77.
    1. Petersen C, Harder D, Abola Z, Alberti D, Becker T, Chardot C, et al. European biliary atresia registries: summary of a symposium. Eur J Pediatr Surg. 2008;18:111–16.
    1. Kumagi T, Drenth JP, Guttman O, Ng V, Lilly L, Therapondos G, et al. Biliary atresia and survival into adulthood without transplantation: a collaborative multicentre clinic review. Liver Int. 2012;32:510–18.
    1. Boberg KM, Lind GE. Primary sclerosing cholangitis and malignancy. Best Pract Res Clin Gastroenterol. 2011;25:753–64.
    1. Bjornsson E, Olsson J, Rydell A, Fredriksson K, Eriksson C, Sjoberg C, et al. Long-term follow-up of patients with alcoholic liver disease after liver transplantation in Sweden: impact of structured management on recidivism. Scand J Gastroenterol. 2005;40:206–16.
    1. Cornberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, Cooper C, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int. 2011;31:30–60.
    1. Rimseliene G, Nilsen O, Klovstad H, Blystad H, Aavitsland P. Epidemiology of acute and chronic hepatitis B virus infection in Norway, 1992-2009. BMC Infect Dis. 2011;11:153.
    1. Dalgard O, Jeansson S, Skaug K, Raknerud N, Bell H. Hepatitis C in the general adult population of Oslo: prevalence and clinical spectrum. Scand J Gastroenterol. 2003;38:864–70.
    1. Hoffmann G, Berglund G, Elmstahl S, Eriksson S, Verbaan H, Widell A, et al. Prevalence and clinical spectrum of chronic viral hepatitis in a middle-aged Swedish general urban population. Scand J Gastroenterol. 2000;35:861–5.
    1. Scaglione S, Kliethermes S, Cao G, Shoham D, Durazo R, Luke A, et al. The Epidemiology of Cirrhosis in the United States: A Population-based Study. J Clin Gastroenterol. 2014 Epub ahead of print.
    1. Mazzaferro V, Bhoori S, Sposito C, Bongini M, Langer M, Miceli R, et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl. 2011;17:S44–57.
    1. Unek T, Karademir S, Arslan NC, Egeli T, Atasoy G, Sagol O, et al. Comparison of Milan and UCSF criteria for liver transplantation to treat hepatocellular carcinoma. World J Gastroenterol. 2011;17:4206–12.
    1. Line PD, Karlsen TH, Boberg KM, Schrumpf E, Fosby B, Bentdal Ø, et al. Outcome after liver transplantation for hepatocellular carcinoma (HCC) on extended criteria. 2012 Abstract presented at The Scandinavian Transplantation Society XXVI Congress, Reykjavik, Iceland, May 9-12.
    1. Koschny R, Schmidt J, Ganten TM. Beyond Milan criteria--chances and risks of expanding transplantation criteria for HCC patients with liver cirrhosis. Clin Transplant. 2009;23:49–60.
    1. Piardi T, Audet M, Odeh M, Panaro F, Cag M, El-ahmar J, et al. Liver transplantation exceeding UCSF criteria: case report of a late recurrence treated by surgery and review of the literature. Eur Surg Res. 2010;44:52–5.
    1. Friman S, Foss A, Isoniemi H, Olausson M, Hockerstedt K, Yamamoto S, et al. Liver transplantation for cholangiocarcinoma: selection is essential for acceptable results. Scand J Gastroenterol. 2011;46:370–5.
    1. Hagness M, Foss A, Line PD, Scholz T, Jorgensen PF, Fosby B, et al. Liver transplantation for nonresectable liver metastases from colorectal cancer. Ann Surg. 2013;257:800–6.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe